(NASDAQ: SKYE) Skye Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.
Skye Bioscience's earnings in 2026 is -$55,924,814.On average, 10 Wall Street analysts forecast SKYE's earnings for 2026 to be -$32,731,216, with the lowest SKYE earnings forecast at -$47,104,112, and the highest SKYE earnings forecast at -$20,678,144. On average, 10 Wall Street analysts forecast SKYE's earnings for 2027 to be -$37,728,017, with the lowest SKYE earnings forecast at -$55,936,133, and the highest SKYE earnings forecast at -$20,327,667.
In 2028, SKYE is forecast to generate -$46,756,973 in earnings, with the lowest earnings forecast at -$70,001,944 and the highest earnings forecast at -$23,481,960.